CytomX Therapeutics Inc (CTMX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CytomX Therapeutics Inc (CTMX) has a cash flow conversion efficiency ratio of -0.145x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.55 Million) by net assets ($107.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CytomX Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how CytomX Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does CytomX Therapeutics Inc carry for a breakdown of total debt and financial obligations.
CytomX Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CytomX Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Scanfil Oyj
HE:SCANFL
|
0.118x |
|
Surge Energy Inc.
TO:SGY
|
0.082x |
|
Lsb Industries Inc
NYSE:LXU
|
0.104x |
|
Pentamaster Corporation Bhd
KLSE:7160
|
0.023x |
|
NioCorp Developments Ltd. Common Stock
NASDAQ:NB
|
-0.003x |
|
Shenzhen Xfh Technology Co Ltd
SHE:300890
|
-0.023x |
|
Xingtong Shipping Co. Ltd.
SHG:603209
|
N/A |
|
Bright Minds Biosciences Inc
NASDAQ:DRUG
|
-0.065x |
Annual Cash Flow Conversion Efficiency for CytomX Therapeutics Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of CytomX Therapeutics Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see CytomX Therapeutics Inc (CTMX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-456.00K | $-86.23 Million | 189.103x | +15912.09% |
| 2023-12-31 | $-47.45 Million | $-56.03 Million | 1.181x | -8.59% |
| 2022-12-31 | $-85.75 Million | $-110.79 Million | 1.292x | +197.01% |
| 2021-12-31 | $89.38 Million | $-119.03 Million | -1.332x | -96.86% |
| 2020-12-31 | $-7.77 Million | $5.26 Million | -0.676x | +75.39% |
| 2019-12-31 | $51.11 Million | $-140.48 Million | -2.748x | -376.32% |
| 2018-12-31 | $130.88 Million | $-75.52 Million | -0.577x | -123.67% |
| 2017-12-31 | $69.90 Million | $170.37 Million | 2.438x | +9514.09% |
| 2016-12-31 | $78.48 Million | $-2.03 Million | -0.026x | +88.09% |
| 2015-12-31 | $126.07 Million | $-27.41 Million | -0.217x | +46.29% |
| 2014-12-31 | $-78.54 Million | $31.80 Million | -0.405x | -323.89% |
| 2013-12-31 | $-44.28 Million | $-8.01 Million | 0.181x | -- |
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic w… Read more